AfroCentric Group Integrated Annual Report 2017

74 / 146

OPERATIONAL REVIEWS
AFROCENTRIC
STRATEGIC OBJECTIVES AFA’S ALIGNMENT TO THESE
Enhance
shareholder value
AfA has performed very well financially in 2016/17, contributing significantly to the
AfroCentric results.
Deliver exceptional
client service
AfA client service continues to be exceptional, with the lowest rates of complaints and
queries received regarding service in the Group.
OPPORTUNITIES AND CHALLENGES
With the expansion of the Group, AfA is capable of integrating
services with other Group companies. Our collaboration
with Pharmacy Direct will ensure improved adherence to
medication, resulting in better clinical outcomes such as viral
load suppression. AfA intends to continue pursuing value chain
optimisation.
Our integration with Medscheme’s Active Disease Risk
Management (“ADRM”) programme has been further enhanced
– our operational processes follow the same template, taking
into account the best of all the managed care products. HIV is
now perceived as a manageable chronic condition rather than
a life-threatening disease. With consistent ART, the lifespan of
an HIV-positive young adult is now almost the same as that of
a non-infected adult.
Global disease management systems advocate moving
away from single disease management to comprehensive
management for all of an individual’s chronic diseases, and
the interplay between them – whether communicable or non-
communicable. Therefore, AfA offers a client scheme or
corporate more holistic patient management, leveraging all the
technology developments such as the Electronic Health Record
(“EHR”) and wellness activities within the Group.
NCDs are a new pandemic facing South Africa. The greatest
risk to AfA is the affordability challenge for South Africans. As
medical schemes lose scheme members due to affordability
constraints, so too does AfA lose registered patients. The
company is committed to find a model that allows for its
registered patients to retain their access to treatment and
disease support, even if they are compelled to reduce their
spend on health insurance. Further, with schemes striving to
keep their contributions low, reduction on all expenditure
becomes a focus. Therefore, AfA needs to demonstrate its
value, while finding service models that ensure the cost of
delivering the AfA product is as low as possible.
OUTLOOK
As the country moves towards integration between the public
and private sector to serve all South Africans equitably, AfA is
poised to offer its services to a larger population of HIV-infected
South Africans so that they enjoy the clinical and life expectancy
outcomes that the current AfA population have enjoyed for over
10 years.
We aim to provide a valuable service by improving the clinical
outcomes of people living with HIV, which in turn reduces the
financial risk to employers and medical schemes. AfA is
progressing towards achieving the UNAIDS treatment targets,
whereby 90% of our patients will have viral loads suppressed.
We were pleased to welcome Bonitas option plan (“BonCap”)
and Liberty members into the AfA universe and are looking
forward to receiving and assessing their pathology results and
then consistently improving their viral load results.
While the outlook for AfA remains favourable, expansion into
new markets and significant client growth is challenging in the
current environment.
Visit the Aid for Aids website,
AID FOR AIDS CONTINUED
AFROCENTRIC GROUP 70